NGeneBio엔젠바이오
354200 · KOSDAQ · ₩354200 · 엔젠바이오
₩681▼ ₩31 (4.35%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 13.9% | 17.9% | 37.7% | −3.2% | 37.6% | 33.5% |
| Operating margin | −15.1% | −39.0% | −282.5% | −308.6% | −78.1% | −121.9% |
| Net margin | −12.1% | −26.1% | −221.9% | −293.5% | −88.8% | −117.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +96.8% | +273.2% | +30.8% | −60.5% | +53.8% | — |
| Operating income growth | +23.8% | +48.5% | −19.7% | −56.1% | +1.5% | — |
| Net income growth | +9.0% | +56.1% | +1.1% | −30.5% | −16.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −23.9% | −27.8% | −75.9% | −61.4% | −33.0% | −24.8% |
| Return on assets | −5.8% | −12.8% | −37.1% | −26.1% | −19.7% | −19.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 277.9% | 220.2% | 86.1% | 160.5% | 121.8% | 29.0% |
| Net debt to equity | 168.2% | 131.1% | 12.8% | −51.4% | −55.7% | −27.5% |
| Current ratio | 44.8% | 50.8% | 93.2% | 113.5% | 148.5% | 339.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: NGeneBio / 엔젠바이오 / 354200 / KRX:354200
Source: KRX statistical information